The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the application of CAR-T cells has been limited by antigen escape and on-target, off-tumor toxicities. Therefore, it may be a potentially effective strategy to select appropriate targets and to combine multi-antigen-targeted CAR-T cells with “OR”, “AND” and “NOT” Boolean logic gates. We summarize the current limitations of CAR-T cells as well as the efficacy and safety of logic-gated CAR-T cells in antitumor therapy. This review will help to explore more optimized strategies to expand the CAR-T cell therapeutic window.

中文翻译：

---

用于癌症治疗的多抗原靶向嵌合抗原受体 T 细胞。


美国食品和药物管理局 (FDA) 批准两种嵌合抗原受体修饰的 T 细胞类型用于治疗血液恶性肿瘤，这是免疫疗法的一个里程碑；然而，CAR-T细胞的应用受到抗原逃逸和靶向、肿瘤外毒性的限制。因此，选择合适的靶点，将多抗原靶向的CAR-T细胞与“或”、“与”、“非”布尔逻辑门结合起来，可能是一种潜在有效的策略。我们总结了目前 CAR-T 细胞的局限性以及逻辑门控 CAR-T 细胞在抗肿瘤治疗中的有效性和安全性。本次综述将有助于探索更优化的策略来扩大 CAR-T 细胞的治疗窗口。